🇺🇸 FDA
Pipeline program

Rilvegostomig

D702BC00001

Phase 3 small_molecule active

Quick answer

Rilvegostomig for Non-small Cell Lung Cancer is a Phase 3 program (small_molecule) at AstraZeneca with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca
Indication
Non-small Cell Lung Cancer
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials